Niclosamide

STAT Inhibitors Drug Pipeline Markets Research 2022: Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Apoptosis, News, Nausea, Discovery, Daewoong Pharmaceutical, Jiangsu Hengrui Medicine, STAT3, III, STAT5, Protein, Hepatic stellate cell, STAT5B, Acquisition, II, Infection, Clinical trial, STAT1, JAK3, STAT6, STAT5A, JAK2, COVID, STAT inhibitors, Niclosamide, Therapy, Oxidative phosphorylation, JAK1, Tyrosine, Oligonucleotide, Signal, STAT, Vomiting, Fatigue, JAK, Peptidomimetic, Pharmaceutical industry

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their drug candidate based on STAT Inhibitors in the most advanced stage, i.e.
  • The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D.

First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference

Retrieved on: 
Monday, February 7, 2022
Niclosamide, Nutrient, EPI, Exocrine pancreatic insufficiency, Company, Ulcerative colitis, Digestion, Patient, Fats, Cystic fibrosis, Diarrhea, FW, COVID-19, Pharmaceutical industry

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Key Points: 
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • First Wave BioPharmas niclosamide portfolio is led by two clinical programs in Phase 2 clinical trials: FW-COV for COVID-19 gastrointestinal infections and FW-UP for ulcerative proctitis (UP) and ulcerative proctosigmoiditis.
  • The Company is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
  • First Wave BioPharma is headquartered in Boca Raton, Florida.

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19

Retrieved on: 
Thursday, January 27, 2022
Food, Microbiology, CEO, Program, Pharmacokinetics, SAD, COVID-19, MAD, Single, Volunteering, Risk, Therapy, Safety, Emergency Use Authorization, NASDAQ, Severe acute respiratory syndrome coronavirus 2, BID, Tacrolimus, Disease, Company, Infection, Solubility, Annual report, UNION, Absorption, TFF, Niclosamide, GLOBE, Drug, FDA, Pharmaceutical industry

AUSTIN, Texas, Jan. 27, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial (CT.gov identifier NCT05168644) of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases.

Key Points: 
  • We are pleased with the continued progress of TFFs internal pipeline including inhaled niclosamide, which we believe could provide a safer, convenient and effective option to treat COVID-19, said Glenn Mattes, CEO of TFF Pharmaceuticals.
  • TFF Pharmaceuticals intends to utilize its Thin Film Freezing technology to produce an inhaled formulation of niclosamide to target the lungs directly where SARS-CoV-2 infection occurs, avoiding gastrointestinal side effects and overcoming the bioavailability limitations of systemic administration.
  • Following results from the Phase 1 trial, UNION Therapeutics A/S has an option to exclusively license the dry powder formulation of niclosamide and is responsible for the next phase of development.
  • TFF Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.

Improved Pharma Announces Pharmaceutical R&D Efforts in 2021

Retrieved on: 
Friday, January 14, 2022
Research, AAPS PharmSciTech, PDF, Canadian International Council, Poly, Excipient, DSC, Sumitomo Chemical, Lapatinib, Plasma, Salt (chemistry), Efficiency, Environment, SSCI, Bedaquiline, THF, Particle-size distribution, X-ray crystallography, Dow Chemical Company, Risk, FBZ, XRD, Publication, Adult, AAPS, NMR, Ion, Pharmacy, Solubility, ASD, Section, Tuberculosis, Solvent, RH, Ageing, PEO Soldier, Solution, Computer scientist, NCL, TGA, International Journal of Pharmaceutics, Behavior, IR, Particle size, ADFS, Journal, CSO, Atomic mass, USFDA, Niclosamide, TB, Tablet, Population, PEO, Salt, Consultant, Polymer, ADF, Drug development, Heckel, Patent, Journal of Pharmaceutical Sciences, Ethylene oxide, Pharmaceutical industry, Fine chemical, Sulfur, Animal, Aluminium, Indometacin

WEST LAFAYETTE, Ind., Jan. 14, 2022 /PRNewswire-PRWeb/ -- Developing new tools and advancing pharmaceutical development is a key part of Improved Pharma's mission.

Key Points: 
  • WEST LAFAYETTE, Ind., Jan. 14, 2022 /PRNewswire-PRWeb/ -- Developing new tools and advancing pharmaceutical development is a key part of Improved Pharma's mission.
  • In 2021, the results from several research and development projects were published with our team of consultants and collaborators.
  • "This past year has been very exciting for the Improved Pharma team," exclaims Dr. Stephen Byrn, CSO of Improved Pharma.
  • Improved Pharma is a research, consulting, and information company dedicated to improving pharmaceutical methods, formulations, and processes.

First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program

Retrieved on: 
Thursday, January 13, 2022
PERT, Nature, Patient, International, Stomach, Niclosamide, Clinical trial, Fats, Weight loss, BOCA, Diarrhea, Nutrient, Malabsorption, NASDAQ, EPI, CEO, Absorption, Cystic Fibrosis Foundation, GLOBE, Standard of care, Cystic fibrosis, Ulcerative colitis, U.S. Securities and Exchange Commission, Acquisition, USPTO, Program, Patent, Company, Method, Digestion, Food, Yarrowia, INN, Steatorrhea, First wave, Lipase, Security (finance), Abdominal pain, Exocrine pancreatic insufficiency, International nonproprietary name, FW, Medical imaging, Pharmaceutical industry

BOCA RATON, Fla., Jan. 13, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, today provided an update on its adrulipase (FW-EPI) clinical program and advances involving adrulipase.

Key Points: 
  • BOCA RATON, Fla., Jan. 13, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, today provided an update on its adrulipase (FW-EPI) clinical program and advances involving adrulipase.
  • First Wave BioPharma has filed two new provisional patent applications pertaining to adrulipase with the U.S. Patent and Trademark Office (USPTO).
  • This is an important step in our efforts to strengthen and expand our adrulipase intellectual property portfolio as we advance the FW-EPI clinical development program, said James Sapirstein, President and CEO of First Wave BioPharma.
  • First Wave BioPharma is pursuing parallel monotherapy and combination therapy clinical pathways with adrulipase.

First Wave BioPharma Announces Further Adjournment of Annual Meeting

Retrieved on: 
Friday, January 7, 2022
Time, FW, Nutrient, Company, Patient, Exocrine pancreatic insufficiency, Diarrhea, Board of directors, Ulcerative colitis, Proposal 2, EST, Annual Meetings of the International Monetary Fund and the World Bank Group, NASDAQ, EPI, BOCA, Cystic fibrosis, Board, Fats, GLOBE, Niclosamide, Digestion, First wave, Director, Annual general meeting, Holding company, Pharmaceutical industry, Shareholder

The adjourned meeting will be held at 9:00 a.m. EST on January 14, 2022 at the following url: www.virtualshareholdermeeting.com/FWBI2021 .

Key Points: 
  • The adjourned meeting will be held at 9:00 a.m. EST on January 14, 2022 at the following url: www.virtualshareholdermeeting.com/FWBI2021 .
  • Annual Meeting of Stockholders of First Wave BioPharma, Inc.
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • First Wave BioPharma is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

Retrieved on: 
Thursday, January 6, 2022
Clinical trial, Vomiting, Safety, Severe acute respiratory syndrome coronavirus 2, FW, COVID-19, Food, Viral load, Acquisition, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nutrient, Emergency Use Authorization, Company, Patient, Exocrine pancreatic insufficiency, Diarrhea, Ulcerative colitis, Gastrointestinal disease, COVID, U.S. Securities and Exchange Commission, Biopharma LLC, Security (finance), CEO, NASDAQ, Șaeș, EPI, Infection, FDA, GI, Cystic fibrosis, Participation, Fats, World, Institut Pasteur Korea, GLOBE, WHO, EUA, Abdominal pain, Digestion, Part, First wave, World Health Organization, SARS2, Pharmaceutical industry, Niclosamide, Omicron, Delta

BOCA RATON, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has completed enrollment for Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV as an outpatient treatment for COVID-19-related gastrointestinal (GI) infections. FW-COV is a proprietary, oral, tablet formulation of micronized niclosamide being developed to remove SARS-CoV-2 (SARS2), the virus that causes COVID-19, from the GI tract.

Key Points: 
  • No FW-COV drug-related serious adverse events (SAEs) have been reported from the trial participants.
  • First Wave BioPharma expects to report top-line data in the first half of 2022.
  • We are very pleased to complete enrollment of the second part of the RESERVOIR trial and look forward to reporting top-line data in the coming months, stated James Sapirstein, President and CEO of First Wave BioPharma.
  • This is an important milestone for First Wave and the development of FW-COV.

First Wave BioPharma to Participate in Two Investor Conferences in January 2022

Retrieved on: 
Tuesday, January 4, 2022
FW, EPI, U.S. Securities and Exchange Commission, Digestion, Diarrhea, Ulcerative colitis, Niclosamide, Clinical trial, Company, Exocrine pancreatic insufficiency, First wave, Patient, Nutrient, Security (finance), Acquisition, Fats, Cystic fibrosis, Pharmaceutical industry

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Key Points: 
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • The Companys niclosamide portfolio is led by two clinical programs in Phase 2 clinical trials: FW-COV, for COVID-19 gastrointestinal infections and FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis.
  • First Wave BioPharma is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
  • This press release may contain certain statements relating to future results which are forward-looking statements.

First Wave BioPharma Announces Adjournment of Annual Meeting

Retrieved on: 
Friday, December 17, 2021
FW, Annual general meeting, Board of directors, Digestion, Director, Company, Board, BOCA, Annual Meetings of the International Monetary Fund and the World Bank Group, Exocrine pancreatic insufficiency, Fats, Time, NASDAQ, Niclosamide, First wave, Patient, Ulcerative colitis, Cystic fibrosis, EPI, GLOBE, Nutrient, EST, Proposal 2, Diarrhea, Holding company, Pharmaceutical industry, Shareholder

The adjourned meeting will be held at 9:00 a.m. EST on January 7, 2022 at the following url: www.virtualshareholdermeeting.com/FWBI2021 .

Key Points: 
  • The adjourned meeting will be held at 9:00 a.m. EST on January 7, 2022 at the following url: www.virtualshareholdermeeting.com/FWBI2021 .
  • Annual Meeting of Stockholders of First Wave BioPharma, Inc.
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • First Wave BioPharma is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants

Retrieved on: 
Tuesday, December 7, 2021
Human, University of Geneva, Research, Delta, Plasma protein binding, Niclosamide, COVID-19, KOSDAQ, Technology, Hospital, Mutation, University of Oxford, Omicron, Drug resistance, Thought, CP, Space Delta 6, Vaccine, Yale University, COVID, Patient, Cell, Method, Organization, DDS, University of California, San Francisco, Virus, Korea Research Institute of Bioscience and Biotechnology, CEO, Science (journal), Degenerative disease, Trial of the century, University of Baghdad, University, RNA, KRIBB, Autophagy, Clinical trial, Interview, Immunity, CTO, PLOS, Severe acute respiratory syndrome coronavirus 2, WHO, Pharmaceutical industry

SEOUL, South Korea, Dec. 7, 2021 /PRNewswire/ -- Experimental results have been published for the first time showing that an antiviral drug containing niclosamide, an anthelmintic, in combination with dexamethasone, an anti-inflammatory drug, produces a 'synergistic effect' for severe COVID-19 patients. There is a growing possibility that a combination therapy for severe COVID-19 patients, for which there is currently no suitable treatment, may be developed for the first time in Korea.

Key Points: 
  • CP-COV03, a niclosamide-based oral antiviral drug, to cure COVID-19 variants
    CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19.
  • It is a 'host-directed' drug that focuses on the host cell, unlike existing vaccines and antiviral drugs that target the virus.
  • This is the first study result that confirmed the synergistic effect of an oral antiviral drug with dexamethasone as COVID-19 combo treatment.
  • Dr. Kim also stated, "Because CP-COV03 targets host cells, it will be a broad-spectrum antiviral drug that can treat COVID-19 and its variants."